TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11303372
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose interleukin-2 (IL-2) therapy with prior autologous vaccines.
Study: 1446996
Drug: Propranolol treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol treatment for 4 to 6 weeks after a 2-week placebo phase
Study: 2870353
Drug: LHRH (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH (1.2 mg/day intranasally)
Study: 2870353
Drug: LHRH and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH and human chorionic gonadotropin (before treatment)
Study: 28661264
Drug: Solifenacin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin (5 mg once daily for 15 days)
Study: 25617983
Drug: alglucosidase alfa
Normalized name: Alglucosidase Alfa
DrugBank: Alglucosidase alfa (DB01272)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: alglucosidase alfa 20 mg/kg/week
Study: 25617983
Drug: alglucosidase alfa
Normalized name: Alglucosidase Alfa
DrugBank: Alglucosidase alfa (DB01272)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: alglucosidase alfa 40 mg/kg/2 weeks
Study: 25617983
Drug: standard ERT
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard ERT (alglucosidase alfa 20 mg/kg/2 weeks)
Study: 19538690
Drug: Disorder-specific psychotherapies
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disorder-specific psychotherapies (CBT, interpersonal, family, and group therapies)
Study: 19538690
Drug: Adjunctive psychotherapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive psychotherapies
Study: 17426802
Drug: Cisatracurium 0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.10 mg.kg(‐1)
Study: 17426802
Drug: Cisatracurium 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.15 mg.kg(‐1)
Study: 17426802
Drug: Rocuronium 0.60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.60 mg.kg(‐1)
Study: 17426802
Drug: Rocuronium 0.90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.90 mg.kg(‐1)
Study: 11576567
Drug: Oral sulindac
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sulindac (100 mg) every 12 hours until 34 weeks' gestation
Study: 7820328
Drug: Test drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug (piracetam)
Study: 7820328
Drug: Reference drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug (piracetam)
Study: 787460
Drug: Betahistine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine (16 mg t.i.d.)
Study: 29280453
Drug: Topical OTD70DERM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical OTD70DERM (RGTA)
Study: 19539211
Drug: Prochymal(R) at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochymal(R) at a dose of either 2 or 8 million MSCs/kg in combination with corticosteroids
Study: 19539211
Drug: Prochymal(R) at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochymal(R) at a dose of either 2 or 8 million MSCs/kg
Study: 16927304
Drug: Dutasteride 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 3.5 mg
Study: 3354254
Drug: Paediatric attenuated
Normalized name: varicella, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paediatric attenuated influenza vaccine (two doses, intranasally, 1 month apart)
Study: 26222759
Drug: Aromatherapy (lavender
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatherapy (lavender oil) in addition to standard medical treatment (diclofenac sodium, 75 mg intramuscularly)
Study: 26222759
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy (diclofenac sodium, 75 mg intramuscularly)
Study: 21443293
Drug: Combination Behavioral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Behavioral Intervention (CBI) only
Study: 21443293
Drug: Study medications
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study medications (naltrexone, acamprosate, naltrexone + acamprosate, placebo) with medication management (MM)
Study: 19015204
Drug: Tacrolimus ointment
Normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus ointment 0.03% applied once daily, 3 times per week
Study: 19015204
Drug: Vehicle applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vehicle applied once daily, 3 times per week
Study: 12647487
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined hormone replacement therapy (HRT)
Study: 9782217
Drug: Dey combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dey combination solution (albuterol-ipratropium)
Study: 8145958
Drug: Itraconazole 100
Normalized name: itraconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 100 mg once daily for 4 weeks
Study: 8145958
Drug: Griseofulvin 500
Normalized name: griseofulvin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin 500 mg once daily for 4 weeks
Study: 3139877
Drug: Methotrexate 10
Normalized name: methotrexate 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 10 mg IM weekly
Study: 3139877
Drug: Sodium aurothiomalate
Normalized name: Sodium aurothiomalate
DrugBank: Sodium aurothiomalate (DB09276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium aurothiomalate (GSTM) 50 mg IM weekly
Study: 31532277
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (CT) involving intramuscular testosterone injection and testosterone ointment application
Study: 31532277
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection monotherapy (IMIM)
Study: 30529119
Drug: Topical heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical heparin treatment
Study: 26091244
Drug: aTIV after
Approvals — FDA: no, EMA: no, PMDA: no
Description: aTIV after control vaccine
Study: 24334642
Drug: Verbal assessments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbal assessments administered in-person
Study: 19294693
Drug: Atorvastatin (ATV)
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (ATV) 80 mg/dL for two months (n = 14)
Study: 19294693
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (CT) for two months (n = 11)
Study: 15470336
Drug: 750 mL
Normalized name: ALCOHOL 750 mL in 1 L TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mL red wine (13.5% by volume)
Study: 15470336
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sildenafil and red wine
Study: 30905430
Drug: Behavioral weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral weight loss intervention with weekly self-monitoring, tailored feedback on diet and exercise goals, and dietitian and provider counseling.
Study: 25784358
Drug: Ranibizumab monotherapy
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab monotherapy (RM)
Study: 25784358
Drug: Ranibizumab plus
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab plus verteporfin photodynamic therapy (RV)
Study: 24026876
Drug: Cisplatin/pirarubicin (CITA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin/pirarubicin (CITA) chemotherapy
Study: 24026876
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HDC) with stem cell transplantation (SCT)
Study: 19154270
Drug: Tenoxicam 20
Normalized name: tenoxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 20 mg orally for 3 days before orthodontic activation
Study: 19154270
Drug: Tenoxicam 20
Normalized name: tenoxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 20 mg orally for 3 days after orthodontic activation
Study: 17410029
Drug: Gemcitabine (G)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (G) 1250 mg/m, given on days 1 and 14, repeated every 28 days for up to four cycles.
Study: 17410029
Drug: Gemcitabine-carboplatin (GCb)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine-carboplatin (GCb) 1250 mg/m of G plus carboplatin area under the curve of 3, given on days 1 and 14, repeated every 28 days for up to four cycles.
Study: 11479880
Drug: sICAM‐1 levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: sICAM‐1 levels in group III (1760.0 ± 717.5 ng/mL)
Study: 11479880
Drug: sVCAM‐1 levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: sVCAM‐1 levels in group III (1932.9 ± 282.6 ng/mL)
Study: 11479880
Drug: sVCAM‐1 levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: sVCAM‐1 levels in group II with portal hypertension (PH) (1253.0 ± 245.1 ng/mL)
Study: 9510981
Drug: Dolasetron mesylate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron mesylate, 200 mg after a high-fat breakfast
Study: 9510981
Drug: Dolasetron mesylate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron mesylate, 200 mg after an overnight fast
Study: 9063763
Drug: 1 g.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g. day-1 of allithiamine for 5 days
Study: 1946576
Drug: Theophylline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (100 mg/kg/day)
Study: 1946576
Drug: Propranolol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (25 mg/kg/day)
Study: 1946576
Drug: Propranolol (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (higher dose)
Study: 7053279
Drug: Verapamil (240,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (240, 360, and 480 mg/day)
Study: 24245960
Drug: Standard-dose prasugrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose prasugrel
Study: 24245960
Drug: Double maintenance-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double maintenance-dose clopidogrel
Study: 22586253
Drug: Arterolane maleate
Normalized name: maleate
DrugBank: Arterolane (DB19027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arterolane maleate plus piperaquine phosphate (AM-PQP) 150 mg and 750 mg respectively
Study: 18341677
Drug: Tolevamer potassium
Normalized name: Potassium
DrugBank: Tolevamer (DB01344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolevamer potassium sodium 15 g day(-1) for 9 days
Study: 18341677
Drug: Tolevamer potassium
Normalized name: Potassium
DrugBank: Tolevamer (DB01344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolevamer potassium sodium 6 g day(-1) for 9 days
Study: 15715683
Drug: Dual ETA/ETB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual ETA/ETB receptor antagonism with BQ123 and BQ788 (10 nmol min(‐1)) during ramipril treatment
Study: 15715683
Drug: Ramipril 10
Normalized name: ramipril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 10 mg o.d. for 3 months
Study: 9371403
Drug: BEP (bleomycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEP (bleomycin, etoposide, and cisplatin) chemotherapy
Study: 4019953
Drug: 6‐methyl‐prednisolone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6‐methyl‐prednisolone (1 mg/kg) intravenous bolus
Study: 4019953
Drug: 6‐methyl‐prednisolone (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6‐methyl‐prednisolone (32 mg once a day, orally) for 8 days
Study: 29522226
Drug: Nepafenac 0.3%
Normalized name: NEPAFENAC 0.3% OPH SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nepafenac 0.3% ophthalmic suspension once daily
Study: 29522226
Drug: Nepafenac 0.1%
Normalized name: NEPAFENAC 0.1% SUSP,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nepafenac 0.1% ophthalmic suspension three times a day
Study: 26386921
Drug: Bosentan 4
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan 4 mg/kg twice-daily (can be down-titrated to 2 mg/kg if not tolerated)
Study: 26386921
Drug: Bosentan 4
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan 4 mg/kg twice-daily
Study: 22994348
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with house dust mite allergen extracts
Study: 17321581
Drug: Grass pollen
Normalized name: grass pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass pollen mix (sublingual immunotherapy) for 2 years
Study: 17321581
Drug: Grass pollen
Normalized name: grass pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass pollen mix (sublingual immunotherapy)
Study: 26947668
Drug: Watermelon extract
Normalized name: watermelon extract 50 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watermelon extract (6 g daily for 6 weeks)
Study: 23430142
Drug: 1% (w/w)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% (w/w) AHYP cream applied twice daily for 4 weeks
Study: 23430142
Drug: Control cream
Normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control cream applied twice daily for 4 weeks
Study: 21138533
Drug: n‐3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 PUFA (2 g/day) and antioxidant vitamins C (1 g/day) and E (400 IU/day)
Study: 12525463
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (600 micro g every 3 h for a maximum of three doses)
Study: 12525463
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (600 micro g every 3 h for a maximum of three doses)
Study: 10865219
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride (25 mg twice daily) plus calcium (1000 mg/day)
Study: 10865219
Drug: Intermittent etidronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent etidronate (400 mg/day for 14 days) followed by calcium (1000 mg/day for 76 days)
Study: 25617159
Drug: Dexmedetomidine (min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (min 0.2 µg/kg/h‐max 1.0 µg/kg/h)
Study: 25617159
Drug: Propofol (min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (min 1.0 mg/kg/h‐max 3.0 mg/kg/h)
Study: 23724525
Drug: Oral medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medroxyprogesterone acetate (MPA) for three months
Study: 23724525
Drug: Oral medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medroxyprogesterone acetate (MPA) for six months
Study: 20816027
Drug: Topiramate (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (mean endpoint dose = 177.8 ± 134.2 mg/d; range, 50-400 mg/d)
Study: 15641760
Drug: Fluoridated milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoridated milk (5 ppm; total amount 1.25 mg F)
Study: 11393606
Drug: Multicomponent smoking
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent smoking treatment (MST)
Study: 11393606
Drug: MST plus
Normalized name: MST 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: MST plus generalization training of smoking cessation to drug and alcohol cessation (MST+G)
Study: 11393606
Drug: MST+G
Normalized name: MST 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: MST+G
Study: 9252088
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (500 mg/day) plus methotrexate (10 mg/week)
Study: 3795978
Drug: Yohimbine (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (18 mg yohimbine/day)
Study: 31694861
Drug: RVT-1502 5
Normalized name: RVT-801
DrugBank: ACG-801 (DB17659)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVT-1502 5 mg
Study: 31694861
Drug: RVT-1502 10
Normalized name: RVT-801
DrugBank: ACG-801 (DB17659)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVT-1502 10 mg
Study: 31694861
Drug: RVT-1502 15
Normalized name: RVT-801
DrugBank: ACG-801 (DB17659)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVT-1502 15 mg
Study: 29394207
Drug: Epidural injections
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injections of local anesthetic with corticosteroid (n = 200)
Study: 18332704
Drug: Surfactant administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant administration without endotracheal intubation
Study: 10318654
Drug: Clopidogrel and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel and aspirin (CA group)
Study: 10318654
Drug: Ticlopidine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine and aspirin (TA group)
Study: 8905888
Drug: Standard chest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chest physical therapy and postural drainage (CPT/PD)
Study: 28270280
Drug: CTPA on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTPA on high-pitch scanning mode at 70 kV tube voltage with 15 ml contrast medium (Group B)
Study: 28270280
Drug: CTPA on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTPA on conventional scanning mode (120 kV, 80 ml contrast medium) (Group A)
Study: 24805262
Drug: DHA (30
Normalized name: Gesticare DHA (30) Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (30 mg/kg/d)
Study: 17075807
Drug: Prednisone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (30 mg/day for 2 weeks, 20 mg/day for 1 week, and 10 mg/day for 1 week)
Study: 7931253
Drug: MDL 72974A
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDL 72974A 1 mg
Study: 7931253
Drug: MDL 72974A
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDL 72974A 12 mg
Study: 7931253
Drug: MDL 72974A
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDL 72974A 24 mg
Study: 18364321
Drug: Taiwanese traditional
Normalized name: Taiwanese cheesewood whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taiwanese traditional herbal diet (TTHD) consisting of analgesic herbs (paeony root: licorice root=1:1) and Taiwanese tonic vegetable soup (Lilii bulbus, Nelumbo seed, and Jujube fruit)
Study: 18364321
Drug: Taiwanese tonic
Normalized name: Ellis Tonic
DrugBank: Zinc sulfate, unspecified form (DB14548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taiwanese tonic vegetable soup without analgesic herbs (control group)
Study: 15014006
Drug: Autologous formalin‐fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous formalin‐fixed tumor vaccine (AFTV)
Study: 12409970
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (75 mg daily) in patients with serum creatinine > 1.3 mg/dl
Study: 12409970
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (75 mg daily) in subgroups at higher global baseline risk or higher initial blood pressures
Study: 9613307
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g EMLA (group E)
Study: 9613307
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml 1% mepivacaine (group M)
Study: 9613307
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml 0.25% bupivacaine (group B)
Study: 7584486
Drug: XZ‐CD5 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: XZ‐CD5 0.1 mg kg‐1 day‐1 intravenously with high‐dose methyl‐prednisolone for 10, 14 or 17 doses
Study: 7584486
Drug: XZ‐CD5 and
Approvals — FDA: no, EMA: no, PMDA: no
Description: XZ‐CD5 and cyclosporine (CSA) for 17 doses
Study: 31437302
Drug: DNL104 (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNL104 (a centrally penetrant RIPK1 inhibitor)
Study: 31254640
Drug: Duloxetine 20
Normalized name: duloxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 20 mg/day titrated to 40 mg/day
Study: 26576593
Drug: Imatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib plus bevacizumab, 7.5 mg/kg i.v. every 3 weeks
Study: 26576593
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg (standard) or 800 mg (for patients with exon 9 KIT mutations)
Study: 23662289
Drug: CR oxycodone/CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR oxycodone/CR naloxone (10 mg/5 mg every 12 h, titrated to 20 mg/10 mg, 30 mg/15 mg, or 40 mg/20 mg)
Study: 23662289
Drug: CR oxycodone/CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR oxycodone/CR naloxone
Study: 23356027
Drug: 1 month
Normalized name: LUPRON-PED 15MG (1 MONTH) SA INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 month of daily rifampin and daily ofloxacin
Study: 19635893
Drug: 1 year
Normalized name: COVID vacc 2024-2025 (5-11 years) (Pfizer)/PF 10 mcg/0.3 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 year of WHO MDT plus an initial 1 month of daily rifampin and daily ofloxacin
Study: 9364542
Drug: Docetaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (100 mg/m2) as a single agent
Study: 9364542
Drug: Docetaxel (20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (20% to 21%) after failing cisplatin-based chemotherapy
Study: 9364542
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2) and Cisplatin (75 mg/m2)
Study: 9364542
Drug: Docetaxel (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (90 mg/m2 without G-CSF support) and Carboplatin
Study: 9364542
Drug: Docetaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (100 mg/m2 with G-CSF support) and Carboplatin
Study: 3629488
Drug: Iron preparations
Normalized name: IRON PREPARATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron preparations combined with vitamins B12 and B6, copper sulfate, and the combination of iron with the vitamin B group and copper sulfate.
Study: 3629488
Drug: Iron preparations
Normalized name: IRON PREPARATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron preparations administered for injection.
Study: 3629488
Drug: Subsequent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent therapy after hemoglobin normalization.
Study: 3629488
Drug: Iron preparations
Normalized name: IRON PREPARATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron preparations combined with other preparations.
Study: 23844613
Drug: Sodium selenite
Normalized name: Sodium selenite
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Sodium selenite 200 mcg daily for 6 months